NCT02045836 - Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older | Biotech Hunter

Enrollment

865

Participants

Timeline

Start Date

March 5, 2014

Primary Completion Date

July 2, 2015

Study Completion Date

June 17, 2016

Conditions

Herpes ZosterHerpes Zoster Vaccine

Interventions

BIOLOGICAL

Herpes Zoster vaccine GSK 1437173A

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

BIOLOGICAL

Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™

One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Trial Locations (9)

GSK Investigational Site, Tallinn

GSK Investigational Site, Tallinn

GSK Investigational Site, Columbia

GSK Investigational Site, Tartu

GSK Investigational Site, Wichita

GSK Investigational Site, Golden

GSK Investigational Site, Coquitlam

GSK Investigational Site, Truro

GSK Investigational Site, Greater Sudbury